Categories Analysis, Other Industries

Tilray, Canopy Growth could emerge winners in a year’s time

Tilray’s (TLRY) enthusiastic IPO in July and the stock’s subsequent high jump to $13.27 billion valuation have put the entire cannabis industry in the scanner. Skeptics see the soaring valuation as a sign of a bubble, thanks to its outlandish fundamentals.

Tilray is doubtlessly overpriced at the moment. However, this may be one of those occasions when you need to read the market, not from the numbers, but from the possibilities.

With Canada legalizing the recreational use of marijuana next week, a pot market with potential for about $10 billion in sales will open up. Major players including Tilray, Canopy Growth (CGC) and Aurora Cannabis will battle it out with over 100 smaller players in Canada to capture a major share of the market.

tilray, canopy stocks
Photo by Sharon McCutcheon on Unsplash

Ahead of the legalization next week, all these companies are using up their cash reserves to invest in production and distribution activities. However, since the Canadian market is not huge enough to feed all these players, many firms are definitely going to fall apart in the next one-year period.

Though the global pot market is expected to grow to around $220 billion by 2030, no other region apart from Canada is likely to see an immediate legalization of marijuana. Even the best bets – the US and Europe – will take some time before full-fledged legalization is in place. Therefore, for the time being, pot companies are restricted to a smaller market.

With high confidence and more resources to back its operations, Tilray and Canopy are expected to have an edge over smaller players in the Canadian market. Since both the companies operate in two different sub-segments, it is likely that both will co-exist without causing much damage to the prospects of the other.

Tilray soars on CEO’s optimistic views on marijuana industry

So Tilray or Canopy?

At the moment, Canopy would prove to be a better bet than Tilray, primarily because of two reasons. One, Canopy is slightly less overvalued than Tilray. Two, analysts’ projections indicate that Canopy will post higher topline growth in 2019 than its rival.

Separately, Constellation Brands’ (STZ) recent $4 billion investment in Canopy gives it more firepower to boost revenue growth. This is compared to Tilray, whose cash reserves are just over $25 million.

Meanwhile, if you can wait till the prices to drop to a more reasonable level, it would probably count as a better investment decision.

Most Popular

IPO Alert: What to look for when Boundless Bio goes public

Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.

Nike (NKE) bets on innovation and partnerships to return to high growth

Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company

Walgreens Boots Alliance set to report earnings next week. Here’s what to expect

Walgreens Boots Alliance, Inc. (NASDAQ: WBA), the drug store chain that is expanding into a diversified healthcare provider, is on a restructuring drive aimed at better aligning the business with

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top